


# FUNDAMENTALS OF PATHOLOGY

*MEDICAL COURSE AND STEP 1 REVIEW*

2018 EDITION



**HUSAIN A. SATTAR, MD**

Associate Professor of Pathology  
Associate Director of Clinical Pathophysiology and Therapeutics  
The University of Chicago  
Pritzker School of Medicine  
Chicago, Illinois

**pathoma.com**

Chicago • 2018

PATHOMA.COM

*Fundamentals of Pathology: Medical Course and Step 1 Review, 2018 Edition*

ISBN 978-0-9832246-3-1

Printed in the United States of America.

Copyright © 2018 by Pathoma LLC.

Previous editions copyrighted 2011, 2013, 2014, 2015, 2016, 2017.

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form, or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without prior permission in writing from the publisher (email: [info@pathoma.com](mailto:info@pathoma.com)).

#### Disclaimer

*Fundamentals of Pathology* aims at providing general principles of pathology and its associated disciplines and is not intended as a working guide to patient care, drug administration or treatment. Medicine is a constantly evolving field and changes in practice regularly occur. It is the responsibility of the treating practitioner, relying on independent expertise and knowledge of the patient, to determine the best treatment and method of application for the patient. Neither the publisher nor the author assume any liability for any injury and/or damage to persons or property arising from or related to the material within this publication.

Furthermore, although care has been taken to ensure the accuracy of information present in this publication, the author and publisher make no representations or warranties whatsoever, express or implied, with respect to the completeness, accuracy or currency of the contents of this publication. This publication is not meant to be a substitute for the advice of a physician or other licensed and qualified medical professional. Information presented in this publication may refer to drugs, devices or techniques which are subject to government regulation, and it is the responsibility of the treating practitioner to comply with all applicable laws.

This book is printed on acid-free paper.

Published by Pathoma LLC.

<http://www.pathoma.com>

[info@pathoma.com](mailto:info@pathoma.com)

Cover and page design by Olaf Nelson, Chinook Design, Inc.

<http://www.chinooktype.com>

**Purchase online at [www.pathoma.com](http://www.pathoma.com).**

# CONTENTS

|                    |   |     |
|--------------------|---|-----|
| <i>Chapter 1.</i>  | Growth Adaptations, Cellular Injury, and Cell Death .....   | 1   |
| <i>Chapter 2.</i>  | Inflammation, Inflammatory Disorders, and Wound Healing ... | 11  |
| <i>Chapter 3.</i>  | Principles of Neoplasia .....                               | 23  |
| <i>Chapter 4.</i>  | Hemostasis and Related Disorders.....                       | 31  |
| <i>Chapter 5.</i>  | Red Blood Cell Disorders.....                               | 41  |
| <i>Chapter 6.</i>  | White Blood Cell Disorders .....                            | 53  |
| <i>Chapter 7.</i>  | Vascular Pathology .....                                    | 65  |
| <i>Chapter 8.</i>  | Cardiac Pathology .....                                     | 73  |
| <i>Chapter 9.</i>  | Respiratory Tract Pathology .....                           | 85  |
| <i>Chapter 10.</i> | Gastrointestinal Pathology .....                            | 99  |
| <i>Chapter 11.</i> | Exocrine Pancreas, Gallbladder, and Liver Pathology.....    | 115 |
| <i>Chapter 12.</i> | Kidney and Urinary Tract Pathology .....                    | 125 |
| <i>Chapter 13.</i> | Female Genital System and Gestational Pathology.....        | 137 |
| <i>Chapter 14.</i> | Male Genital System Pathology.....                          | 151 |
| <i>Chapter 15.</i> | Endocrine Pathology .....                                   | 159 |
| <i>Chapter 16.</i> | Breast Pathology .....                                      | 175 |
| <i>Chapter 17.</i> | Central Nervous System Pathology .....                      | 181 |
| <i>Chapter 18.</i> | Musculoskeletal Pathology .....                             | 195 |
| <i>Chapter 19.</i> | Skin Pathology .....  | 205 |
| <i>Index</i>       | .....   | 213 |

## USING THIS BOOK

This work is intended as a review for students during their preclinical years and while preparing for examinations, such as the USMLE™. To this effect, the organization of this book follows that of most primary texts in the field and parallels the syllabus used in pathophysiology courses in medical schools throughout the United States. Ample space is provided for students to make notes during course study and while viewing the online videos that cover each section of the text ([www.pathoma.com](http://www.pathoma.com)).

We recommend that students use *Fundamentals of Pathology* during their medical courses, taking notes in the margin as pertinent topics are covered. When exam time comes around, these notes will likely be invaluable.

For examination preparation, we suggest students read the material first, then listen to the online lecture, and then reread the material to develop a solid grasp of each topic. One should not become disheartened if they are not able to retain all the information contained herein. This deceptively slim volume covers a tremendous amount of material, and repetition will be a key aid as you progress in your studies.

An effort has been made to emphasize concepts and principles over random facts, the forest rather than the trees. Attention to the same by the student will provide a deeper, more meaningful understanding of human disease. We must always remind ourselves that ultimately our goal is to learn, to share, and to serve. *Fundamentals of Pathology* was developed with this goal in mind.

Husain A. Sattar, MD  
Chicago, Illinois

All rights reserved.

## ACKNOWLEDGMENTS

This work would not have been possible without the support and encouragement of those around me. To begin with, I would like to acknowledge Shaykh Zulfiqar Ahmad, whose clear vision has guided me to horizons I would never have known. My family is to be acknowledged for their limitless sacrifice, in particular the constant encouragement and support of my wife Amina, who has proved through the years to be the wind under my wings. Thomas Krausz, MD and Aliya Husain, MD (both Professors of Pathology at the University of Chicago) deserve particular mention for their valuable advice and guiding vision, both in the development of this book as well as my career. Special thanks to the multiple reviewers at medical centers throughout the country for their critical comments, in particular Mir Basharath Alikhan, MD (Pathology resident, University of Chicago) and Joshua T.B. Williams (Class of 2013, Pritzker School of Medicine, University of Chicago) for their extensive review. Olaf Nelson (Chinook Design, Inc.) is to be commended for his excellent layout and design. Finally, I would be remiss without acknowledging my students, who give meaning to what I do.

**Purchase online at [www.pathoma.com](http://www.pathoma.com).**

# Growth Adaptations, Cellular Injury, and Cell Death

1

## GROWTH ADAPTATIONS

### I. BASIC PRINCIPLES

- A. An organ is in homeostasis with the physiologic stress placed on it.
- B. An increase, decrease, or change in stress on an organ can result in growth adaptations.

### II. HYPERPLASIA AND HYPERTROPHY

- A. An increase in stress leads to an increase in organ size.
  - 1. Occurs via an increase in the size (hypertrophy) and/or the number (hyperplasia) of cells
- B. Hypertrophy involves gene activation, protein synthesis, and production of organelles.
- C. Hyperplasia involves the production of new cells from stem cells.
- D. Hyperplasia and hypertrophy generally occur together (e.g., uterus during pregnancy).
  - 1. Permanent tissues (e.g., cardiac muscle, skeletal muscle, and nerve), however, cannot make new cells and undergo hypertrophy only.
  - 2. For example, cardiac myocytes undergo hypertrophy, not hyperplasia, in response to systemic hypertension (Fig. 1.1).
- E. Pathologic hyperplasia (e.g., endometrial hyperplasia) can progress to dysplasia and, eventually, cancer.
  - 1. A notable exception is benign prostatic hyperplasia (BPH), which does not increase the risk for prostate cancer.

### III. ATROPHY

- A. A decrease in stress (e.g., decreased hormonal stimulation, disuse, or decreased nutrients/blood supply) leads to a decrease in organ size (atrophy).
  - 1. Occurs via a decrease in the size and number of cells
- B. Decrease in cell number occurs via apoptosis.
- C. Decrease in cell size occurs via ubiquitin-proteasome degradation of the cytoskeleton and autophagy of cellular components.
  - 1. In ubiquitin-proteasome degradation, intermediate filaments of the cytoskeleton are “tagged” with ubiquitin and destroyed by proteasomes.
  - 2. Autophagy of cellular components involves generation of autophagic vacuoles. These vacuoles fuse with lysosomes whose hydrolytic enzymes breakdown cellular components.

### IV. METAPLASIA

- A. A change in stress on an organ leads to a change in cell type (metaplasia).
  - 1. Most commonly involves change of one type of surface epithelium (squamous, columnar, or urothelial) to another
  - 2. Metaplastic cells are better able to handle the new stress.
- B. Barrett esophagus is a classic example.


1. Esophagus is normally lined by nonkeratinizing squamous epithelium (suited to handle friction of a food bolus).
  2. Acid reflux from the stomach causes metaplasia to nonciliated, mucin-producing columnar cells (better able to handle the stress of acid, Fig. 1.2).
- C. Metaplasia occurs via reprogramming of stem cells, which then produce the new cell type.
1. Metaplasia is reversible, in theory, with removal of the driving stressor.
  2. For example, treatment of gastroesophageal reflux may reverse Barrett esophagus.
- D. Under persistent stress, metaplasia can progress to dysplasia and eventually result in cancer.
1. For example, Barrett esophagus may progress to adenocarcinoma of the esophagus.
  2. A notable exception is apocrine metaplasia of breast, which carries no increased risk for cancer.
- E. Vitamin A deficiency can also result in metaplasia.
1. Vitamin A is necessary for differentiation of specialized epithelial surfaces such as the conjunctiva covering the eye.
  2. In vitamin A deficiency, the thin squamous lining of the conjunctiva undergoes metaplasia into stratified keratinizing squamous epithelium. This change is called keratomalacia (Fig. 1.3).
- F. Mesenchymal (connective) tissues can also undergo metaplasia.
1. A classic example is myositis ossificans in which connective tissue within muscle changes to bone during healing after trauma (Fig. 1.4).

## V. DYSPLASIA

- A. Disordered cellular growth
- B. Most often refers to proliferation of precancerous cells
  1. For example, cervical intraepithelial neoplasia (CIN) represents dysplasia and is a precursor to cervical cancer.
- C. Often arises from longstanding pathologic hyperplasia (e.g., endometrial hyperplasia) or metaplasia (e.g., Barrett esophagus)
- D. Dysplasia is reversible, in theory, with alleviation of inciting stress.
  1. If stress persists, dysplasia progresses to carcinoma (irreversible).

## VI. APLASIA AND HYPOPLASIA

- A. Aplasia is failure of cell production during embryogenesis (e.g., unilateral renal agenesis).
- B. Hypoplasia is a decrease in cell production during embryogenesis, resulting in a relatively small organ (e.g., streak ovary in Turner syndrome).



**Fig. 1.1** Left ventricular hypertrophy. (Courtesy of Aliya Husain, MD) **Fig. 1.2** Barrett esophagus.


## CELLULAR INJURY

### I. BASIC PRINCIPLES


- A. Cellular injury occurs when a stress exceeds the cell's ability to adapt.
- B. The likelihood of injury depends on the type of stress, its severity, and the type of cell affected.
  1. Neurons are highly susceptible to ischemic injury; whereas, skeletal muscle is relatively more resistant.
  2. Slowly developing ischemia (e.g., renal artery atherosclerosis) results in atrophy; whereas, acute ischemia (e.g., renal artery embolus) results in injury.
- C. Common causes of cellular injury include inflammation, nutritional deficiency or excess, hypoxia, trauma, and genetic mutations.

### II. HYPOXIA

- A. Low oxygen delivery to tissue; important cause of cellular injury
  1. Oxygen is the final electron acceptor in the electron transport chain of oxidative phosphorylation.
  2. Decreased oxygen impairs oxidative phosphorylation, resulting in decreased ATP production.
  3. Lack of ATP (essential energy source) leads to cellular injury.
- B. Causes of hypoxia include ischemia, hypoxemia, and decreased O<sub>2</sub>-carrying capacity of blood.
- C. Ischemia is decreased blood flow through an organ. Arises with
  1. Decreased arterial perfusion (e.g., atherosclerosis)
  2. Decreased venous drainage (e.g., Budd-Chiari syndrome)
  3. Shock—generalized hypotension resulting in poor tissue perfusion
- D. Hypoxemia is a low partial pressure of oxygen in the blood (Pao<sub>2</sub> < 60 mm Hg, Sao<sub>2</sub> < 90%). Arises with
  1. High altitude—Decreased barometric pressure results in decreased PAO<sub>2</sub>.
  2. Hypoventilation—Increased PACO<sub>2</sub> results in decreased PAO<sub>2</sub>.
  3. Diffusion defect—PAO<sub>2</sub> not able to push as much O<sub>2</sub> into the blood due to a thicker diffusion barrier (e.g., interstitial pulmonary fibrosis)
  4. V/Q mismatch—Blood bypasses oxygenated lung (circulation problem, e.g., right-to-left shunt), or oxygenated air cannot reach blood (ventilation problem, e.g., atelectasis).
- E. Decreased O<sub>2</sub>-carrying capacity arises with hemoglobin (Hb) loss or dysfunction. Examples include
  1. Anemia (decrease in RBC mass)—Pao<sub>2</sub> normal; Sao<sub>2</sub> normal
  2. Carbon monoxide poisoning



**Fig. 1.3** Keratomalacia. (Courtesy of motherchildnutrition.org)




**Fig. 1.4** Myositis Ossificans. (Reprinted with permission from orthopaedia.com)

- i. CO binds hemoglobin more avidly than oxygen— $P_{aO_2}$  normal;  $S_{aO_2}$  decreased
  - ii. Exposures include smoke from fires and exhaust from cars or gas heaters.
  - iii. Classic finding is cherry-red appearance of skin.
  - iv. Early sign of exposure is headache; significant exposure leads to coma and death.
3. Methemoglobinemia
    - i. Iron in heme is oxidized to  $Fe^{3+}$ , which cannot bind oxygen— $P_{aO_2}$  normal;  $S_{aO_2}$  decreased
    - ii. Seen with oxidant stress (e.g., sulfa and nitrate drugs) or in newborns
    - iii. Classic finding is cyanosis with chocolate-colored blood.
    - iv. Treatment is intravenous methylene blue, which helps reduce  $Fe^{3+}$  back to  $Fe^{2+}$  state.

### III. REVERSIBLE AND IRREVERSIBLE CELLULAR INJURY

- A. Hypoxia impairs oxidative phosphorylation resulting in decreased ATP.
- B. Low ATP disrupts key cellular functions including
  1.  $Na^+$ - $K^+$  pump, resulting in sodium and water buildup in the cell
  2.  $Ca^{2+}$  pump, resulting in  $Ca^{2+}$  buildup in the cytosol of the cell
  3. Aerobic glycolysis, resulting in a switch to anaerobic glycolysis. Lactic acid buildup results in low pH, which denatures proteins and precipitates DNA.
- C. The initial phase of injury is reversible. The hallmark of reversible injury is cellular swelling.
  1. Cytosol swelling results in loss of microvilli and membrane blebbing.
  2. Swelling of the rough endoplasmic reticulum (RER) results in dissociation of ribosomes and decreased protein synthesis.
- D. Eventually, the damage becomes irreversible. The hallmark of irreversible injury is membrane damage.
  1. Plasma membrane damage results in
    - i. Cytosolic enzymes leaking into the serum (e.g., cardiac troponin)
    - ii. Additional calcium entering into the cell
  2. Mitochondrial membrane damage results in
    - i. Loss of the electron transport chain (inner mitochondrial membrane)
    - ii. Cytochrome *c* leaking into cytosol (activates apoptosis)
  3. Lysosome membrane damage results in hydrolytic enzymes leaking into the cytosol, which, in turn, are activated by the high intracellular calcium.
- E. The end result of irreversible injury is cell death.



**Fig. 1.5** Coagulative necrosis of kidney. **A**, Gross appearance. **B**, Microscopic appearance. **C**, Normal kidney histology for comparison. (A, Courtesy of Aliya Husain, MD)